APR May/June 2022 - 5

Being First Means Doing Something No One
Else Has Ever Done Before... We Do That A Lot.
We have a long history of advancing Endotoxin and Glucan
testing technologies that make a difference.
A History Of Firsts!
1st To Introduce An Animal Free, Recombinant LAL Reagent
1st Large Scale IVF Program To Introduce Horseshoe Crabs Into The Wild
1st To Establish BET Contract Testing Services
1st BET Company Licensed By FDA
Advance your laboratory 's Endotoxin and Glucan
detection capabi litie s into 1st place today.
www. ac c iu s a . c om * 8 8 8 . 3 9 5 . 2 2 2 1
Associates of Cape Cod, Inc.
Your Endotoxin & Glucan Experts
Associates of Cape Cod, Inc. - a Seikagaku Group Company
MKT#21-076

http://www.acciusa.com

APR May/June 2022

Table of Contents for the Digital Edition of APR May/June 2022

Message from the Editor
Editorial Advisory Board
CN Perspectives
Social Media Connections
BIOPHARMACEUTICALS - Long-Acting Injectable Suspensions
ROUNDTABLE - Controlled Release
QC CORNER - Affinity Approaches to Selective, Sensitive MS Assays
DRUG DELIVERY - Introduction to mRNA-LNPs, Their Manufacture and Future Perspectives
BIOPHARMACEUTICALS - A Next-Generation Workforce for Next- Generation Therapies Preparing for Cell and Gene Therapies
MICROBIOLOGY - Optimizing a Viral Testing Strategy
BIOPHARMACEUTICAL - Assuring Quality of Oligonucleotide APIs and DPs
FACILITY TOUR - Growing to Serve: Eurofins’ Portage, Michigan, Facility Expands to Offer New Capabilities and Services
VENDOR VIEWPOINT - Combining the Best of Both Worlds with Semi-Targeted Metabolomics
VENDOR VIEWPOINT - Method Changes for Bacterial Endotoxins Testing (BET): Steps to Follow for a Straightforward Process
An Interview with Tony Saavedra Sievers DataShare Elite Stoftware
Editor's Top Tech
MANUFACTURING - A Discourse on Pharmaceutical cGMP FDA Form 483 Trends: Why are We Re-Living the Same Issues Over the Last 23 Years?
Equipment Focus
MICROBIOLOGY - Cleaning and Disinfection: An Important Pillar of Contamination Control
P.I.N. Points
Advertiser's Index
APR May/June 2022 - Cover1
APR May/June 2022 - Cover2
APR May/June 2022 - 1
APR May/June 2022 - 2
APR May/June 2022 - 3
APR May/June 2022 - 4
APR May/June 2022 - 5
APR May/June 2022 - Message from the Editor
APR May/June 2022 - Editorial Advisory Board
APR May/June 2022 - CN Perspectives
APR May/June 2022 - Social Media Connections
APR May/June 2022 - BIOPHARMACEUTICALS - Long-Acting Injectable Suspensions
APR May/June 2022 - 11
APR May/June 2022 - 12
APR May/June 2022 - 13
APR May/June 2022 - 14
APR May/June 2022 - 15
APR May/June 2022 - 16
APR May/June 2022 - 17
APR May/June 2022 - ROUNDTABLE - Controlled Release
APR May/June 2022 - 19
APR May/June 2022 - 20
APR May/June 2022 - 21
APR May/June 2022 - 22
APR May/June 2022 - 23
APR May/June 2022 - 24
APR May/June 2022 - 25
APR May/June 2022 - 26
APR May/June 2022 - 27
APR May/June 2022 - QC CORNER - Affinity Approaches to Selective, Sensitive MS Assays
APR May/June 2022 - 29
APR May/June 2022 - 30
APR May/June 2022 - 31
APR May/June 2022 - 32
APR May/June 2022 - 33
APR May/June 2022 - 34
APR May/June 2022 - 35
APR May/June 2022 - DRUG DELIVERY - Introduction to mRNA-LNPs, Their Manufacture and Future Perspectives
APR May/June 2022 - 37
APR May/June 2022 - 38
APR May/June 2022 - 39
APR May/June 2022 - 40
APR May/June 2022 - 41
APR May/June 2022 - BIOPHARMACEUTICALS - A Next-Generation Workforce for Next- Generation Therapies Preparing for Cell and Gene Therapies
APR May/June 2022 - 43
APR May/June 2022 - 44
APR May/June 2022 - 45
APR May/June 2022 - MICROBIOLOGY - Optimizing a Viral Testing Strategy
APR May/June 2022 - 47
APR May/June 2022 - 48
APR May/June 2022 - 49
APR May/June 2022 - 50
APR May/June 2022 - 51
APR May/June 2022 - BIOPHARMACEUTICAL - Assuring Quality of Oligonucleotide APIs and DPs
APR May/June 2022 - 53
APR May/June 2022 - 54
APR May/June 2022 - 55
APR May/June 2022 - 56
APR May/June 2022 - 57
APR May/June 2022 - 58
APR May/June 2022 - 59
APR May/June 2022 - FACILITY TOUR - Growing to Serve: Eurofins’ Portage, Michigan, Facility Expands to Offer New Capabilities and Services
APR May/June 2022 - 61
APR May/June 2022 - 62
APR May/June 2022 - VENDOR VIEWPOINT - Combining the Best of Both Worlds with Semi-Targeted Metabolomics
APR May/June 2022 - 64
APR May/June 2022 - 65
APR May/June 2022 - VENDOR VIEWPOINT - Method Changes for Bacterial Endotoxins Testing (BET): Steps to Follow for a Straightforward Process
APR May/June 2022 - 67
APR May/June 2022 - An Interview with Tony Saavedra Sievers DataShare Elite Stoftware
APR May/June 2022 - 69
APR May/June 2022 - Editor's Top Tech
APR May/June 2022 - 71
APR May/June 2022 - MANUFACTURING - A Discourse on Pharmaceutical cGMP FDA Form 483 Trends: Why are We Re-Living the Same Issues Over the Last 23 Years?
APR May/June 2022 - 73
APR May/June 2022 - 74
APR May/June 2022 - 75
APR May/June 2022 - 76
APR May/June 2022 - 77
APR May/June 2022 - 78
APR May/June 2022 - Equipment Focus
APR May/June 2022 - MICROBIOLOGY - Cleaning and Disinfection: An Important Pillar of Contamination Control
APR May/June 2022 - 81
APR May/June 2022 - 82
APR May/June 2022 - 83
APR May/June 2022 - 84
APR May/June 2022 - 85
APR May/June 2022 - P.I.N. Points
APR May/June 2022 - 87
APR May/June 2022 - Advertiser's Index
APR May/June 2022 - Cover3
APR May/June 2022 - Cover4
https://www.nxtbookmedia.com